

Anteo Files its Battery Patent in Key Lithium-ion Markets

30 October 2017

Highlights:

- Anteo's Nano-coating Battery Technology patent has progressed to the National Phase of Examination
- The Patent has been filed broadly in 18 targeted countries
- Strategic approach to commercialisation and analysis of Anteo's battery asset being evaluated

Anteo Diagnostics Ltd (ASX: ADO) ("**Anteo**" or the "**Company**") has progressed its patent related to its surface Nano-coating Technology in batteries to the National Phase of Examination. Anteo has filed its patent application in 18 countries either directly or via the European Patent Organisation where the Company will be targeting 5 member countries.

Anteo has sought to maximise the protection of the Company's Intellectual Property ("**IP**") in key lithium-ion battery markets by choosing to file broadly in important countries such as China, United States, South Korea, Singapore, Japan and Indonesia.

The report conducted by Polaris Battery Labs LLC ("**Polaris**") (announced 18 October 2017) and the initial proof of concept test work that has been conducted provided the Company with the confidence to progress with these Patent filings.

Executive Chairman, Dr John Hurrell, commented "Due to the large number of countries that are important consumers and producers of lithium-ion batteries we have made the decision to file more broadly to ensure we have the extent of patent protection required.

"The investment decision in our IP was made following a third party review by Polaris which provided the confidence to progress our patent protection strategy and also gives us the confidence to progress further research in the growing lithium-ion battery market.

"We look forward to progressing our work that will be focused on providing additional data to demonstrate that our technology can improve energy storage and re-charge times in high capacity lithium-ion batteries which use silicon anodes.

"At the same time we will be conducting further market research to understand the value proposition of our technology to ensure we are well placed commercially to take advantage of this potential growth asset"

ABOUT ANTEO GROUP – Anteo Diagnostics Limited (ADO:ASX) & Subsidiaries

Anteo Group is a global nanochemistry technology and medical supply group, developing, commercialising, manufacturing and distributing products for the life sciences, clinical diagnostics and bioseparations markets, and creating new applications in the energy and medical devices sectors.

Through Anteo Technology, the Anteo Group owns a patented nanochemistry surface engineering technology which unites the strength and stability of covalent binding with the gentleness of passive binding through multi-point chelation. Through the use of its reagents binders, coatings or primers, Anteo provides materials and services for high-value commercial applications. Markets include protein binding and antibody coupling (e.g. point of care devices), primers for in-vivo medical devices and medical drug delivery, and coatings with commercial applications across a broad range of industry sectors, including life sciences, in vitro diagnostics, medical devices and energy.

For more information, please visit www.anteodx.com